Wierda Keyslides
- Home
-
Archive
-
ASH 2022
-
IWWM 2022
-
Highlights Newsletter 1
- Podcast with Prof. Jorge Castillo about long-term follow-up of ibrutinib monotherapy in treatment-naïve Waldenström macroglobulinemia
- Podcast with Prof. Evangelos Terpos about responses to COVID vaccination in patients with plasma cell neoplasms
- Podcast with Prof. Constantine Tam about response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia
- Podcast with Prof. Christian Buske about the long-term follow-up of the iNNOVATE study
-
Highlights Newsletter 2
- Podcast with Prof. Véronique Leblond about a phase II study exploring the “chemo-free” treatment association of idelalisib and obinutuzumab in relapsed or refractory WM
- Podcast with Dr. Marzia Varettoni about the first results of the BIOWM study analysing the genomic landscape of WM patients and novel screening techniques
- Podcast with Dr. Tina Bagratuni about a single-cell analysis of mutated and wildtype MYD88 WM
- Podcast with Dr. Shirley D’Sa about Real-World safety and efficacy of ibrutinib in patients with WM: The UK experience
-
Highlights Newsletter 1
-
EHA 2022
-
ASH 2021
-
EHA 2021
-
ASH 2020
- EBMT2020
-
EHA 2020
-
ASH 2019
-
EHA 2019
-
ASH 2018
-
EHA 2018
-
ASH 2017
-
EHA 2017
-
ASH 2016
-
ASH 2015
-
ASH 2014
-
ASH 2022
-
EHA 2023
-
ASH 2023
Speaker William Wierda
William G. Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
See: Presentation